Cranberry and Skyrizi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cranberry (cranberry) and Skyrizi (risankizumab-rzaa). Common drug interactions include haematoma among females.

The phase IV clinical study analyzes what interactions people have when they take Cranberry and Skyrizi. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Cranberry?

Cranberry has active ingredients of cranberry. It is often used in urinary tract infection. eHealthMe is studying from 5,399 Cranberry users. Check the latest studies of Cranberry.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.



On Jul, 06, 2026

11 people who take Cranberry and Skyrizi together, and have interactions are studied.

Cranberry and Skyrizi drug interactions.

What are the common drug interactions of Cranberry and Skyrizi, by gender? *:

female:

  1. Haematoma (collection of blood outside the blood vessels)
  2. Pain
  3. General physical health deterioration (weak health status)
  4. Head injury
  5. Headache (pain in head)
  6. Hypertension (high blood pressure)
  7. Injection site erythema (redness at injection site)
  8. Limb injury
  9. Memory impairment
  10. Rash erythematous (redness of the skin)

male:

n/a

What are the common drug interactions of Cranberry and Skyrizi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Haematoma (collection of blood outside the blood vessels)
  2. Arrhythmia (irregular heartbeat)
  3. Fall
  4. Fatigue (feeling of tiredness)
  5. Injection site erythema (redness at injection site)
  6. Limb injury
  7. Pain
  8. Pruritus (severe itching of the skin)
  9. Malignant melanoma (skin cancer rises from melancytes)

What are the existing conditions these people have? *

  1. Psoriasis (immune-mediated disease that affects the skin): 10 people, 90.91%
  2. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 27.27%
  3. Urinary Tract Disorder: 1 person, 9.09%
  4. Skin Disorder (skin disease): 1 person, 9.09%
  5. Muscle Spasms (muscle contraction): 1 person, 9.09%
  6. Migraine (headache): 1 person, 9.09%
  7. Menopause (end of monthly cycles in women): 1 person, 9.09%
  8. High Blood Cholesterol: 1 person, 9.09%
  9. Gout (uric acid crystals building up in the body): 1 person, 9.09%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Cranberry and Skyrizi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cranberry and Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cranberry:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cranberry and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Skyrizi and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cranberry and risankizumab-rzaa (the active ingredients of Cranberry and Skyrizi, respectively), and Cranberry and Skyrizi (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: